메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 33, Issue 28, 2015, Pages 3221-
The negative is not so negative: What do we learn from trials with orteronel?
Author keywords

[No Author keywords available]
Indexed keywords

ORTERONEL; PREDNISONE; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;
EID: 84944198341     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.3165     Document Type: Letter
Times cited : (3)
References (9)
  • 1
    • 84925006635 scopus 로고    scopus 로고
    • Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5
    • Fizazi K, Jones R, Oudard S, et al: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 33: 723-731, 2015
    • (2015) J Clin Oncol , vol.33 , pp. 723-731
    • Fizazi, K.1    Jones, R.2    Oudard, S.3
  • 2
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005, 2011
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 3
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197, 2012
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 4
    • 84925016549 scopus 로고    scopus 로고
    • Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC4): A double-blind, multicentre, phase 3, randomised, placebo-controlled trial
    • Saad F, Fizazi K, Jinga V, et al: Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC4): A double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 16: 338-348, 2015
    • (2015) Lancet Oncol , vol.16 , pp. 338-348
    • Saad, F.1    Fizazi, K.2    Jinga, V.3
  • 5
    • 84866948935 scopus 로고    scopus 로고
    • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    • Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13: 983-992, 2012
    • (2012) Lancet Oncol , vol.13 , pp. 983-992
    • Fizazi, K.1    Scher, H.I.2    Molina, A.3
  • 6
    • 84921846878 scopus 로고    scopus 로고
    • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
    • Ryan CJ, Smith MR, Fizazi K, et al: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16: 152-160, 2015
    • (2015) Lancet Oncol , vol.16 , pp. 152-160
    • Ryan, C.J.1    Smith, M.R.2    Fizazi, K.3
  • 7
    • 84925337655 scopus 로고    scopus 로고
    • Failure of ELM-PC 5: An ineffective drug or an unfit end point?
    • Morris MJ: Failure of ELM-PC 5: An ineffective drug or an unfit end point? J Clin Oncol 33: 679-681, 2015
    • (2015) J Clin Oncol , vol.33 , pp. 679-681
    • Morris, M.J.1
  • 8
    • 84924964703 scopus 로고    scopus 로고
    • Moving the goal posts in prostate cancer trials
    • Madan RA, Gulley JL: Moving the goal posts in prostate cancer trials. Lancet Oncol 16: 247-249, 2015
    • (2015) Lancet Oncol , vol.16 , pp. 247-249
    • Madan, R.A.1    Gulley, J.L.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.